Pharma bosses chair committee to stop Brexit breaking the UK's life sciences sector

11 July 2016

The UK government has brought in pharma industry chiefs to co-chair a ministerial group aimed at ensuring Brexit does not damage the country’s life sciences sector.

Sir Andrew Witty and Pascal Soriot, the chief executives of GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN), the UK’s two largest pharma companies, are the co-chairmen of the 15-member group along with life sciences minister George Freeman.

The group held its first meeting last week as the UK starts considering the reality of Brexit, which a parliamentary committee had warned would hit the country’s life sciences sector hard before last month’s referendum.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK